enGene Posts Q3 Loss, Sets BLA Filing for Detalimogene in Q4
ENGN sits 29% above its 52-week low of $1.4.
Summary
enGene reported Q3 2026 results with a net loss of $32.5M ($0.47/share) and cash of $266.3M. The company reiterated plans for a pre-BLA meeting and BLA filing initiation in Q4 2026 for detalimogene in BCG-unresponsive NMIBC. The surfactant safety run-in has been cleared and a new cohort is enrolling. A KOL webinar is set for October 15, 2026. This follows the June 2026 workforce reduction and executive departures; the company is now focused on regulatory execution.
At the time of this announcement, ENGN was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.9M. The 52-week trading range was $1.40 to $12.25. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.